N-Acetylaspartylglutamate (NAAG) is a neuropeptide found in millimolar concentrations in brain that is localized to subpopulations of glutamatergic, cholinergic, GABAergic, and noradrenergic neuronal systems. NAAG is released upon depolarization by a Ca 2؉ -dependent process and is an agonist at mGluR3 receptors and an antagonist at NMDA receptors. NAAG is catabolized to N-acetylaspartate and glutamate primarily by glutamate carboxypeptidase II, which is expressed on the extracellular surface of astrocytes. The levels of NAAG and the activity of carboxypeptidase II are altered in a regionally specific fashion in several neuropsychiatric disorders. 1997 Academic Press
INTRODUCTION
N-Acetylaspartylglutamate (NAAG) was originally identified by Curatolo et al. (1965) in horse brain and subsequently confirmed by Miyamato et al. (1966) in bovine brain. In an attempt to identify brain peptides that might modulate glutamatergic neurotransmission, a prominent HPLC peak of displacement activity for the specific binding of [ 3 H]glutamate to brain membranes in Tris-HCl buffer was identified (Zaczek et al., 1983) . Acid hydrolysis of the peak revealed equimolar concentrations of glutamate and aspartate, and fast atom bombardment mass spectroscopy disclosed that the peptide was NAAG. Quantitative measurements indicated that NAAG achieved concentrations as high as 2 mM in certain brain regions, making it one of the most abundant peptides in brain. A number of endogenous and exogenous substances have been shown to modulate glutamatergic neurotransmission including glycine, kynurenic acid, and polyamines at NMDA receptors and thiazides and concanavalin A at AMPA/KA receptors. However, NAAG itself has received rather modest research attention, yet recent findings suggest that it may serve as an important negative modulator of glutamatergic neurotransmission as well as a significant source of extrasynaptic glutamate. This article will briefly review the current state of knowledge about NAAG and its disposition in brain.
Neuronal Localization
Quantitative assays of the levels of endogenous NAAG reveal an uneven regional distribution in rat brain, with the highest concentrations found in spinal cord and brain stem and 10-fold lower concentrations observed in forebrain structures, including the striatum, cerebral cortex, and hippocampal formation. While data are limited, the concentration of NAAG in human cortex and striatum is substantially higher than that in rat, approximating 0.4 mM (Passani et al., 1997) .
While the neuronal localization of NAAG was inferred from brain lesion studies (Koller et al., 1984) , this was unequivocally established in a series of studies in which polyclonal (Anderson et al., 1986; Blakely et al., 1987) and monoclonal antibodies (Frondoza et al., 1990) directed against a NAAG-carbodiimide-protein
